A leading provider of
innovative DNA Screening solutions
AML1/ETO Translocation, Dual Fusion LPH026
AML1 is fused with ETO in the t(8;21)(q22;q22) translocation. The rearrangement is observed in ~40% of AML M2 patients and less frequently in subgroups M1 and M4. Overall, 7% of AML cases demonstrate the abnormality. Three-way variants of this rearrangement and the t(3;21) (AML1/EVI1) show that juxtaposition of AML1 to the derivative chromosome is consistent and therefore the critical rearrangement.
AML1/ETO Translocation, Dual Fusion Probe
Cat. No. LPH 035
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK